Use of 18F-FDG PET for primary treatment strategy in patients with squamous cell carcinoma of the oropharynx

Journal of Nuclear Medicine

Volumn 48, Issue 5, 2007, Pages 752-757

  Sang, Yoon Kim ^a   Roh, Jong Lyel ^a   Mi, Ra Kim ^b   Jae, Seung Kim ^a   Choi, Seung Ho ^a   Soon, Yuhl Nam ^a   Lee, Sang Wook ^a   Kim, Sung Bae ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Bundang Jaesaeng General Hospital   (South Korea)

Author keywords

18F FDG PET; Oropharynx; Predictive factor; Squamous cell carcinoma; Standardized uptake value

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OROPHARYNX CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; KOREA; METHODOLOGY; MIDDLE AGED; MORTALITY; OROPHARYNX TUMOR; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; STATISTICS; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; KOREA; MALE; MIDDLE AGED; OROPHARYNGEAL NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34250615573     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.039610     Document Type: Article

References (16)

1. Lin DT, Cohen SM, Coppit GL, Burkey BB. Squamous cell carcinoma of the oropharynx and hypopharynx. Otolaryngol Clin North Am. 2005;38:59-74.
2. Weber RS, Peters LJ, Wolf P, Guillamondegui O. Squamous cell carcinoma of the soft palate, uvula, and anterior faucial pillar. Otolaryngol Head Neck Surg. 1988;99:16-23.
3. Levendag P, Nijdam W, Noever I, et al. Brachytherapy versus surgery in carcinoma of tonsillar fossa and/or soft palate: late adverse sequelae and performance status - Can we be more selective and obtain better tissue sparing? Int J Radiat Oncol Biol Phys. 2004;59:713-724.
4. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999;91:2081-2086.
5. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol. 2004;22:69-76.
6. 18F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol. 2002;20:4199-4208.
7. Lowe VJ, Boyd JH, Dunphy FR, et al. Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol. 2000;18:651-658.
8. Minn H, Lapela M, Klemi PJ, et al. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med. 1997;38:1907-1911.
9. 18F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol. 2002;20:1398-1404.
10. Chiesa F, Mauri S, Tradati N, et al. Surfing prognostic factors in head and neck cancer at the millennium. Oral Oncol. 1999;35:590-596.
11. Salesiotis AN, Cullen KJ. Molecular markers predictive of response and prognosis in the patient with advanced squamous cell carcinoma of the head and neck: evolution of a model beyond TNM staging. Curr Opin Oncol. 2000;12:229-239.
12. Reisser C, Eichhorn K, Herold-Mende C, Born AI, Bannasch P. Expression of facilitative glucose transport proteins during development of squamous cell carcinomas of the head and neck. Int J Cancer. 1999;80:194-198.
13. Halfpenny W, Hain SF, Biassoni L, Maisey MN, Sherman JA, McGurk M. FDG-PET: a possible prognostic factor in head and neck cancer. Br J Cancer. 2002;86:512-516.
14. Brun E, Kjellen E, Tennvall J, et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck. 2002;24:127-135.
15. Suntharalingam M, Haas ML, Van Echo DA, et al. Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck. Cancer. 2001;91:548-554.
16. Schuller DE, Grecula JC, Agrawal A, et al. Multimodal intensification therapy for previously untreated advanced resectable squamous cell carcinoma of the oral cavity, oropharynx, or hypopharynx. Cancer. 2002;94:3169-3178.